CY1111524T1 - Νεα συντηγμενα πυρρολοκαρβαζολια - Google Patents

Νεα συντηγμενα πυρρολοκαρβαζολια

Info

Publication number
CY1111524T1
CY1111524T1 CY20111100533T CY111100533T CY1111524T1 CY 1111524 T1 CY1111524 T1 CY 1111524T1 CY 20111100533 T CY20111100533 T CY 20111100533T CY 111100533 T CY111100533 T CY 111100533T CY 1111524 T1 CY1111524 T1 CY 1111524T1
Authority
CY
Cyprus
Prior art keywords
pyrolocarzaol
new powdered
present
pyrrolocarbazoles
powdered
Prior art date
Application number
CY20111100533T
Other languages
English (en)
Inventor
Nadine C Becknell
James L Diebold
Diane E Gingrich
Robert L Hudkins
Dandu R Reddy
Ming Tao
Theodore L Underiner
Allison L Zulli
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of CY1111524T1 publication Critical patent/CY1111524T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)

Abstract

Η παρούσα εφεύρεση αφορά γενικώς επιλεγμένα πυρρολοκαρβαζόλια, συμπεριλαμβανομένων φαρμακευτικών συνθέσεων αυτών και μεθόδων θεραπείας ασθενειών με αυτά. Η παρούσα εφεύρεση κατευθύνεται επίσης σε ενδιάμεσα και διεργασίες για την κατασκευή αυτών των συντηγμένων πυρρολοκαρβαζολίων.
CY20111100533T 2003-12-23 2011-06-01 Νεα συντηγμενα πυρρολοκαρβαζολια CY1111524T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles
EP04815262A EP1704148B1 (en) 2003-12-23 2004-12-23 Novel fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
CY1111524T1 true CY1111524T1 (el) 2015-08-05

Family

ID=34703676

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100533T CY1111524T1 (el) 2003-12-23 2011-06-01 Νεα συντηγμενα πυρρολοκαρβαζολια

Country Status (30)

Country Link
US (4) US7169802B2 (el)
EP (1) EP1704148B1 (el)
JP (1) JP5006046B2 (el)
KR (2) KR20120066057A (el)
CN (1) CN1918162B (el)
AR (1) AR047168A1 (el)
AT (1) ATE500256T1 (el)
AU (1) AU2004309394B2 (el)
BR (1) BRPI0418113B8 (el)
CA (1) CA2549627C (el)
CR (1) CR8519A (el)
CY (1) CY1111524T1 (el)
DE (1) DE602004031672D1 (el)
DK (1) DK1704148T3 (el)
EA (1) EA012295B1 (el)
HK (1) HK1096096A1 (el)
HR (1) HRP20110373T1 (el)
IL (1) IL176384A (el)
IS (1) IS8519A (el)
MA (1) MA28298A1 (el)
MY (2) MY158159A (el)
NO (2) NO336893B1 (el)
NZ (1) NZ548099A (el)
PL (1) PL1704148T3 (el)
PT (1) PT1704148E (el)
RS (1) RS51886B (el)
SG (1) SG149045A1 (el)
SI (1) SI1704148T1 (el)
TW (1) TWI355385B (el)
WO (1) WO2005063763A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP2064178A4 (en) * 2006-09-08 2011-10-05 Merck Canada Inc CATHEPSIN S INHIBITOR PRODRUGS
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
CA2693694A1 (en) * 2007-06-08 2008-12-11 University Of Massachusetts Mixed lineage kinases and metabolic disorders
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
MX2011004306A (es) 2008-10-22 2011-07-28 Genentech Inc Modulacion de degeneracion de axones.
WO2010059795A1 (en) * 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) * 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
CA2748276A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
US8357694B2 (en) * 2008-12-30 2013-01-22 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds
MX2012004638A (es) * 2009-10-22 2012-07-04 Genentech Inc Modulacion de degeneracion de axones.
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
SG185645A1 (en) * 2010-05-18 2012-12-28 Cephalon Inc Method for purifying a fused pyrrolocarbazole derivative
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
CN104981697B (zh) 2013-02-11 2017-08-04 英丘伦有限责任公司 促染色质转录复合物(fact)在癌症中的用途
WO2015047982A2 (en) * 2013-09-26 2015-04-02 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN106572992A (zh) 2014-04-06 2017-04-19 英丘伦有限责任公司 用curaxins进行组合治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP2000516250A (ja) 1996-08-22 2000-12-05 ブリストルーマイヤーズ スクイブ カンパニー インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US7109229B2 (en) * 2000-09-29 2006-09-19 Eli Lilly And Company Methods and compounds for treating proliferative diseases
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
US20060247294A1 (en) 2006-11-02
BRPI0418113B8 (pt) 2021-05-25
TWI355385B (en) 2012-01-01
MA28298A1 (fr) 2006-11-01
EA012295B1 (ru) 2009-08-28
CR8519A (es) 2007-06-06
PT1704148E (pt) 2011-05-25
CA2549627A1 (en) 2005-07-14
SI1704148T1 (sl) 2011-06-30
US7671064B2 (en) 2010-03-02
US8044064B2 (en) 2011-10-25
IL176384A0 (en) 2006-10-05
NO20151245A1 (no) 2015-09-23
DE602004031672D1 (de) 2011-04-14
RS51886B (en) 2012-02-29
MY143373A (en) 2011-04-29
CN1918162B (zh) 2014-05-14
US7169802B2 (en) 2007-01-30
BRPI0418113A (pt) 2007-04-17
AU2004309394B2 (en) 2011-04-28
KR20120066057A (ko) 2012-06-21
DK1704148T3 (da) 2011-06-14
KR20060127069A (ko) 2006-12-11
NO336893B1 (no) 2015-11-23
TW200530243A (en) 2005-09-16
US20100152196A1 (en) 2010-06-17
HRP20110373T1 (hr) 2011-06-30
SG149045A1 (en) 2009-01-29
CN1918162A (zh) 2007-02-21
KR101179372B1 (ko) 2012-09-03
IS8519A (is) 2006-06-22
CA2549627C (en) 2012-12-11
NO20063196L (no) 2006-09-20
NZ548099A (en) 2010-05-28
JP5006046B2 (ja) 2012-08-22
BRPI0418113B1 (pt) 2020-04-14
US8383813B2 (en) 2013-02-26
IL176384A (en) 2015-05-31
EA200601217A1 (ru) 2006-12-29
JP2007516293A (ja) 2007-06-21
US20050143442A1 (en) 2005-06-30
EP1704148A1 (en) 2006-09-27
ATE500256T1 (de) 2011-03-15
AR047168A1 (es) 2006-01-11
PL1704148T3 (pl) 2011-07-29
HK1096096A1 (en) 2007-05-25
AU2004309394A1 (en) 2005-07-14
US20120004253A1 (en) 2012-01-05
MY158159A (en) 2016-09-15
EP1704148B1 (en) 2011-03-02
WO2005063763A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
CY1111524T1 (el) Νεα συντηγμενα πυρρολοκαρβαζολια
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
CY1117681T1 (el) Ρυθμιστες 2,3-διοξυγενασης ινδολοαμινης και μεθοδοι χρησης αυτων
ATE408601T1 (de) Fredericamycin-derivate
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
NO20045589L (no) Nye forbindelser
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1114728T1 (el) Φαρμακοτεχνικη μορφη εισπνοης περιλαμβανουσα παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1106207T1 (el) Αντιιικα παραγωγα νουκλεοζιτων
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1109142T1 (el) Χαρακτηρισμος: σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
CY1109487T1 (el) Ανταγωνιστες τυπου ουριας του υποδοχεα p2y1 χρησιμοι στην αγωγη θρομβωτικων καταστασεων
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1110271T1 (el) Υδατικες παρατεταμενης-απελευθερωσης φαρμακοτεχνικες μορφες πρωτεϊνων